Envigo opens its doors for business on 21 September
Envigo has been created through the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates.
Huntingdon Life Sciences, Harlan Laboratories and three subsidiaries have announced that the combined companies have today re-branded as Envigo.
Brian Cass, CEO, commented: “Today we are delighted to officially re-brand as Envigo. This marks a significant milestone for the five companies that came together to create Envigo and demonstrates the great progress we have made in our integration. Our customers are increasingly seeking partners who can deliver a variety of services in a co-ordinated manner, and the breadth of Envigo’s offering strengthens our ability to deliver on that need.”
Envigo employs 3800 people and has sales approaching $500 million. The company is a top-three provider of non-clinical research services and research models and services to the pharmaceutical, chemical and crop protection industries, as well as academic institutions and government agencies worldwide.
Since the announcement on 24 June 2015 that the five companies were combining to form Envigo customers have shown their support for the new company. Adrian Hardy, COO, added: “We have received very positive comments from customers to the on-going integration of our businesses and to our new name. Today we have become Envigo, and our goal is to establish the company as the number one partner for both customer service and scientific excellence.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.